Stock Events

Collegium Pharmaceutical 

$36.08
7
+$0.66+1.86% Friday 20:00

Statistics

Day High
36.24
Day Low
35.68
52W High
40.95
52W Low
20.95
Volume
376,680
Avg. Volume
348,026
Mkt Cap
1.18B
P/E Ratio
16.86
Dividend Yield
-
Dividend
-

Earnings

9MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.14
0.43
1.01
1.58
Expected EPS
0.75
Actual EPS
1.45

People Also Follow

This list is based on the watchlists of people on Stock Events who follow COLL. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap19.04B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing directly in the pain management market where Collegium also operates.
Johnson & Johnson
JNJ
Mkt Cap372.29B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in various therapeutic areas including pain management, directly overlapping with Collegium's market.
Abbvie
ABBV
Mkt Cap304.29B
AbbVie competes in the specialty pharmaceuticals space, including pain management with its products, which positions it as a competitor to Collegium.
AMGEN
AMGN
Mkt Cap177.72B
Amgen, a biotechnology company, has a portfolio that includes treatments for pain, making it a competitor in some of Collegium's key markets.
Merck &
MRK
Mkt Cap318.55B
Merck & Co., Inc. competes across a broad range of therapeutic areas, including pain management through its innovative and generic drug offerings.
Pfizer
PFE
Mkt Cap169.83B
Pfizer is a global pharmaceutical company with a diverse portfolio, including pain management solutions that compete with Collegium's products.
Pacira BioSciences
PCRX
Mkt Cap901.6M
Pacira Biosciences focuses on non-opioid pain management solutions, offering competitive alternatives to Collegium's opioid-based pain management products.

Analyst Ratings

41$Average Price Target
The highest estimate is $44.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

About

Health Technology
Pharmaceuticals: Other
Manufacturing
Pharmaceutical Preparation Manufacturing
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Show more...
CEO
Joseph Ciaffoni
Employees
197
Country
US
ISIN
US19459J1043
WKN
000A14SUV

Listings

F
DE
354.F
XNAS
US
COLL